Skip to content

QT Variability Pre and Post Cardioversion

QT Variability Pre & Post Cardioversion in Patient's With Atrial Fibrillation

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00885391
Acronym
DCCV
Enrollment
219
Registered
2009-04-22
Start date
2007-01-31
Completion date
2012-03-31
Last updated
2014-12-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial Fibrillation

Keywords

Atrial Fibrillation, Cardioversion, Direct Current Cardioversion, QT Interval

Brief summary

The purpose of this study is to learn whether the chemicals in the blood and urine are different when the heart is atrial fibrillation compared to normal sinus rhythm.

Detailed description

Atrial Fibrillation variably activates the renin-angiotensin-aldosterone system (RAAS), stimulates the sympathetic nervous system, generates oxidant stress, produces natriuretic peptides, and increases ventricular rate. These are interrelated responses and the extent to which these or other pathophysiologic responses determine QT interval during and after Atrial Fibrillation (AF) is unknown. In this study, the QT variability is related to those potential markers in patients with AF undergoing elective DC-cardioversion.

Interventions

None listed

Sponsors

National Institutes of Health (NIH)
CollaboratorNIH
Wake Forest University Health Sciences
CollaboratorOTHER
Vanderbilt University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
21 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* At least 21 years of age * Scheduled to undergo an elective DC-Cardioversion of atrial fibrillation or atrial flutter at Vanderbilt University Medical Center

Exclusion criteria

* Undergoing emergent DC-Cardioversion of atrial fibrillation for hemodynamic instability * Undergoing DC-Cardioversion for post-cardiac surgery * Dual chamber pacemakers

Design outcomes

Primary

MeasureTime frame
QT variability before and after direct current cardioversion1.5

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026